Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study

This study is testing whether adding an immunotherapy drug called adebrelimab to standard chemotherapy before surgery improves outcomes for people with esophageal squamous cell cancer — a type of cancer in the lining of the food pipe. Participants receive treatment before surgery, then have surgery to remove the tumor. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with esophageal squamous cell cancer confirmed by biopsy - Your cancer is at a stage where surgery to fully remove it is planned and possible - You have not had any prior cancer treatment (no chemotherapy, radiation, or surgery for this cancer) - Your heart, liver, kidneys, and blood counts are in acceptable range **You may NOT be eligible if...** - Your tumor has grown into major blood vessels or the airway - You have an active autoimmune disease (like lupus, inflammatory bowel disease, or uncontrolled thyroid disease) - You have had a heart attack, heart failure, or severe heart rhythm problems - You are pregnant or breastfeeding - You have HIV or untreated active tuberculosis - You have had a severe infection requiring hospitalization in the past 4 weeks Talk to your doctor to see if this trial is right for you.